Patolojik servikovajinal simirler ve idrar yolu enfeksiyonu arasında bir ilişki var mıdır?

Abstract

Amaç: Patolojik servikovajinal simirler (anormal sitolojik bulgular, fungal enfeksiyonlar, bakteriyel vajinoz ve inflamasyon) ile idrar yolu enfeksiyonu (İYE) arasındaki ilişkiyi değerlendirmektir. Materyal metod: 222 hastanın Pap ile boyanmış servikovajinal simirlerini değerlendirdik. Patolojik servikovajinal simirleri olan hastalar çalışma grubu (n = 59, %26,6), simirlerinde patolojik bulgu olmayan 163 (%73,8) hasta ise kontrol grubu olarak kabul edildi. Çalışma ve kontrol grupları İYE varlığı açısından karşılaştırıldı. Bulgular: Bu kohortta (n = 222), sırasıyla %5,4, %5,9, %8,6 ve %6,8 oranlarında anormal sitolojik bulgular, bakteriyel vajinoz, mantar enfeksiyonu ve inflamasyon olduğu belirlendi. İYE oranı çalışma ve kontrol gruplarında sırasıyla %5,1 ve %3,1 olarak gösterildi (p = 0,441). Anormal sitolojik bulgular, bakteriyel vajinoz, mantar enfeksiyonu ve inflamasyon varlığı ayrı ayrı değerlendirildiğinde mantar enfeksiyonu olan hastalarda kontrollere göre İYE anlamlı olarak daha sık bulundu (p = 0,039). Sonuç: Mantar enfeksiyonu olan hastalarda İYE'nin daha sık olduğu bulunmuştur.

Keywords

• İdrar yolu enfeksiyonu
• Bakteriyel vajinozis
• mantar enfeksiyonu
• inflamasyon
• anormal sitolojik bulgu
• servikovajinal simir

Is there an association between pathologic cervicovaginal smears and urinary tract infection?

Abstract

Aim: To evaluate the association between pathologic cervicovaginal smears (abnormal cytological findings, fungal infections, bacterial vaginosis, and inflammation) and urinary tract infection (UTI). Materials and Method: We evaluated Pap-stained cervicovaginal smears of 222 patients. Pathologic cervicovaginal smears were accepted as a study group (n = 59, 26.6%) while the remaining 163 (73.8%) patients who had no pathologic smears were accepted as a control group. Study and control groups were compared in terms of the presence of UTI. Results: In this cohort (n = 222), we have demonstrated abnormal cytological findings, bacterial vaginosis, fungal infection, and inflammation with rates of 5.4%, 5.9%, 8.6%, and %6.8, respectively. The rate of UTI was demonstrated to be 5.1% and 3.1% in the study and control groups, respectively (p = 0.441). When the presence of abnormal cytological findings, bacterial vaginosis, fungal infection, and inflammation were considered separately, UTI was found to be significantly more frequent in patients with fungal infection compared to controls (p = 0.039). Conclusion: UTI was found to be more frequent in patients with fungal infection.

Keywords

• Urinary tract infection
• Bacterial vaginosis
• fungal infection
• inflammation
• abnormal cytological finding
• cervicovaginal smear

References

1. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002; 113 Suppl 1A:5S–13S. Doi: 10.1016/s0002-9343(02)01054-9
2. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon 2003; 49(2):53–70. Doi: 10.1067/mda.2003.7
3. Hooton TM, Fihn SD, Johnson C, Roberts PL, Stamm WE. Association between bacterial vaginosis and acute cystitis in women using diaphragms. Arch Intern Med 1989; 149(9):1932–6.
4. Hillebrand L, Harmanli OH, Whiteman V, Khandelwal M. Urinary tract infections in pregnant women with bacterial vaginosis. Am J Obstet Gynecol 2002; 186(5):916–7. Doi: 10.1067/mob.[phone]
5. Özel M, Kaymak O, Birgili N, Çelen Ş, Erdoğan M, Danışman N. Treatment of non-complicated lower urinary tract infection in pregnancy: single dose Fosfomycin Tromethamine versus multiple dose Nitrofurantoin. Gynecol Obstet Reprod Med 2011; 17:20–3.
6. Sumati A, Saritha N. Association of urinary tract infection in women with bacterial vaginosis. J Glob Infect Dis 2009; 1(2):151–2. Doi: 10.4103/0974-777X.56254
7. Özmen Beşer E, Ceran B, Sari FN, Bezirganoğlu H, Alyamaç Dizdar E, Tayman C, et al. Jinekoloji - Obstetrik ve Neonatoloji Tıp Dergisi 2020; 17(2):328–30. Doi: 10.38136/jgon.677916
8. Lewis AL, Gilbert NM. Roles of the vagina and the vaginal microbiota in urinary tract infection: evidence from clinical correlations and experimental models. GMS Infect Dis 2020; 8:Doc02. Doi: 10.3205/id000046

9. Stapleton AE. The vaginal microbiota and urinary tract infection. Urin Tract Infect 2016; 4(6):79–86. Doi: 10.1128/microbiolspec.UTI-0025-2016
10. Rosca AS, Castro J, Sousa LGV, Cerca N. Gardnerella and vaginal health: the truth is out there. FEMS Microbiol Rev 2020; 44(1):73–105. Doi: 10.1093/femsre/fuz027
11. Donmez HG, Cagan M, Fadiloglu E, Unal C, Onder SC, Beksac MS. Is bacterial vaginosis associated with autoimmune antibody positivity? Cytopathology 2020; 31(4):298–302. Doi: 10.1111/cyt.12846
12. Işik G, Demirezen Ş, Dönmez HG, Beksaç MS. Bacterial vaginosis in association with spontaneous abortion and recurrent pregnancy losses. J Cytol 2016; 33(3):135–40. Doi: 10.4103/0970-9371.188050
13. Gilbert NM, O’Brien VP, Lewis AL. Transient microbiota exposures activate dormant Escherichia coli infection in the bladder and drive severe outcomes of recurrent disease. PLoS Pathog 2017; 13(3):1–19. Doi: 10.1371/journal.ppat.1006238
14. Demirezen Ş, Dönmez HG, Özcan M, Beksaç MS. Evaluation of the relationship between fungal infection, neutrophil leukocytes and macrophages in cervicovaginal smears: Light microscopic examination. J Cytol 2015; 32(2):79–84. Doi: 10.4103/0970-9371.160544
15. Eckert LO, Koutsky LA, Kiviat NB, Krone MR, Stevens CE, Eschenbach DA. The inflammatory papanicolaou smear: What does it mean? Obstet Gynecol 1995; 86(3):360–6. Doi: 10.1016/0029-7844(95)00196-X
16. Baka S, Tsirmpa I, Chasiakou A, Tsouma I, Politi E, Gennimata V, et al. Inflammation on the cervical papanicolaou smear: Evidence for infection in asymptomatic women? Infect Dis Obstet Gynecol 2013; 2013:184302. Doi: 10.1155/2013/184302
17. Donmez HG, Tanacan A, Unal C, Fadiloglu E, Onder SC, Portakal O, et al. Human papillomavirus infection and autoimmune disorders: A tertiary center experience. Pathog Dis 2019; 77(3):ftz028. Doi: 10.1093/femspd/ftz028.
18. Nayar R, Wilbur DC. The Pap test and Bethesda 2014. Cancer Cytopathol 2015; 123(5):271–81. Doi: 10.1002/cncy.21521.
19. Barber AE, Norton JP, Spivak AM, Mulvey MA. Urinary tract infections: current and emerging management strategies. Clin Infect Dis 2013; 57(5):719–24. Doi: 10.1093/cid/cit284.
20. Haider G, Zehra N, Munir AA, Haider A. Risk factors of urinary tract infection in pregnancy. J Pak Med Assoc 2010; 60(3):213–6.
21. Kodner CM, Thomas Gupton EK. Recurrent urinary tract infections in women: Diagnosis and management. Am Fam Physician 2010; 82(6):638–43.
22. Yu Y, Sikorski P, Bowman-Gholston C, Cacciabeve N, Nelson KE, Pieper R. Diagnosing inflammation and infection in the urinary system via proteomics. J Transl Med 2015; 13(1):1–14. Doi: 10.1186/s12967-015-0475-3
23. Harmanli OH, Cheng GY, Nyirjesy P, Chatwani A, Gaughan JP. Urinary tract infections in women with bacterial vaginosis. Obstet Gynecol 2000; 95:710–12.
24. Ceccarani C, Foschi C, Parolin C, D’Antuono A, Gaspari V, Consolandi C, et al. Diversity of vaginal microbiome and metabolome during genital infections. Sci Rep 2019; 9(1):1–12. Doi: 10.1038/s41598-019-50410-x
25. Imirzalioglu C, Hain T, Chakraborty T, Domann E. Hidden pathogens uncovered: Metagenomic analysis of urinary tract infections. Andrologia 2008; 40(2):66–71. Doi: 10.1111/j.1439-0272.2007.00830.x